Documente Academic
Documente Profesional
Documente Cultură
ScienceDirect
www.sciencedirect.com
Pole femme et enfant, groupe hospitalier universitaire Paris Seine Saint-Denis, site Jean-Verdier, avenue du 14-Juillet, 93140 Bondy, France
UFR SMBH Leonard-de-Vinci, universite Paris-13, 93000 Bobigny, France
I N F O A R T I C L E
R E S U M E
Historique de larticle :
Recu le 30 juin 2014
Accepte le 17 juillet 2014
t 2014
Disponible sur Internet le 20 aou
Le choix de lannexectomie homolaterale en cas de tumeur limite unilaterale doit repondre a` la fois a` un
objectif carcinologique (limiter le risque de recidive), de fertilite et sintegrer dans la prise en charge
globale dun couple en cas de desir de grossesse. Lannexectomie unilaterale est une option legitime en
cas de desir de grossesse par rapport au risque de recidive et de survie. Lidentication dun groupe a` haut
risque de recidive est necessaire. Lannexectomie unilaterale est une option envisageable an de
preserver la fertilite en cas de tumeur unilaterale bien que les donnees sur la reserve ovarienne sont
manquantes. Lannexectomie unilaterale doit etre envisage en situation dinfertilite. Une fecondation in
vitro, si elle est indiquee, est possible en particulier en labsence de facteur de mauvais pronostic apre`s
annexectomie. La place de la cryopreservation de tissu ovarien ou de la maturation in vitro reste a` denir.
2014 Elsevier Masson SAS. Tous droits reserves.
Mots cles :
Tumeur limite de lovaire
Annexectomie
Fertilite
Recidive
AMP
A B S T R A C T
Keywords:
Borderline ovarian tumor
Adnexectomy
Fertility
Recurrence
ART
To perform an adnexectomy in case of unilateral borderline tumor must consider the risk of recurrence,
the preservation of fertility, and to integrate a global comprehensive management of a couple.
Adnexectomy can be considering as a legitimate option when the woman desire a pregnancy. The risk of
recurrence is low and the global survey high. Identication of woman with a high risk of recurrence is
necessary. Adnexectomy can be considering as a legitimate option to preserve fertility in case of
unilateral tumor. However, ovarian reserve data are missing after the surgery. Adnexectomy can be
considering for the management of infertile woman with unilateral borderline tumor. IVF can be
performed in the absence of any poor prognosis factor. Management with ovarian cryopreservation and
In vitro Maturation remain unclear.
2014 Elsevier Masson SAS. All rights reserved.
1. Introduction
Les tumeurs ovariennes dites limite surviennent principalement chez des femmes non menopausees dont 1/3 des cas avant
lage de 40 ans [1]. Le recul progressif de lage de la premie`re
grossesse ainsi que leur meilleur pronostic par comparaison aux
* Auteur correspondant.
Adresse e-mail : jeremy.boujenah@gmail.com (J. Boujenah).
http://dx.doi.org/10.1016/j.gyobfe.2014.07.027
1297-9589/ 2014 Elsevier Masson SAS. Tous droits reserves.
636
637
638
[25] Przybycin CG, Kurman RJ, Ronnett BM, Shih I-M, Vang R. Are all pelvic
(nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol
2010;34(10):140716.
[26] Tang S, Onuma K, Deb P, Wang E, Lytwyn A, Sur M, et al. Frequency of serous
tubal intraepithelial carcinoma in various gynecologic malignancies: a study
of 300 consecutive cases. Int J Gynecol Pathol 2012;31(2):10310.
[27] Nunes N, Ambler G, Foo X, Naftalin J, Widschwendter M, Jurkovic D. Use of the
IOTA simple rules for the diagnosis of ovarian cancer: a meta-analysis. Ultrasound Obstet Gynecol 2014. http://dx.doi.org/10.1002/uog.1343.
[28] Thomassin-Naggara I, Balvay D, Aubert E, Dara E, Rouzier R, Cuenod CA, et al.
Quantitative dynamic contrast-enhanced MR imaging analysis of complex
adnexal masses: a preliminary study. Eur Radiol 2012;22(4):73845.
[29] Bazot M, Haouy D, Dara E, Cortez A, Dechoux-Vodovar S, Thomassin-Naggara
I. Is MRI a useful tool to distinguish between serous and mucinous borderline
ovarian tumours? Clin Radiol 2013;68(1):e18.
[30] Poncelet C, Fauvet R, Yazbeck C, Coutant C, Darai E. Impact of serum tumor
marker determination on the management of women with borderline ovarian
tumors: multivariate analysis of a French multicentre study. Eur J Surg Oncol
2010;36(11):106672.
[31] Braicu EI, Van Gorp T, Nassir M, Richter R, Chekerov R, Gasimli K, et al.
Preoperative HE4 and ROMA values do not improve the CA125 diagnostic
value for borderline tumors of the ovary (BOT) a study of the TOC Consortium. J Ovarian Res 2014;7:49.
[32] Zacharakis D, Thomakos N, Biliatis I, Rodolakis A, Simou M, Daskalakis G, et al.
Ultrasonographic markers and preoperative CA-125 to distinguish between
borderline ovarian tumors and stage I ovarian cancer. Acta Obstet Gynecol
Scand 2013;92(3):28592.
[33] Obermair A, Tang A, Kondalsamy-Chennakesavan S, Ngan H, Zusterzeel P,
Quinn M, et al. Nomogram to predict the probability of relapse in patients
diagnosed with borderline ovarian tumors. Int J Gynecol Cancer 2013;
23(2):2647.
[34] Bendifallah S, Ballester M, Uzan C, Fauvet R, Morice P, Darai E. Nomogram to
predict the recurrence in patients with early and advanced stages of mucinous
and serous borderline ovarian tumors. Am J Obstet Gynecol 2014. http://
dx.doi.org/10.1016/j.ajog.
[35] Bellati F, Ruscito I, Gasparri ML, Antonilli M, Pernice M, Vallone C, et al. Effects
of unilateral ovariectomy on female fertility outcome. Arch Gynecol Obstet
2014. http://dx.doi.org/10.1007/s00404-014-3194-8 [Epub ahead of print].
[36] Bjelland EK, Wilkosz P, Tanbo TG, Eskild A. Is unilateral oophorectomy
associated with age at menopause? A population study (the HUNT2 Survey)
Hum Reprod 2014;29(4):83541.
[37] Khan Z, Gada RP, Tabbaa ZM, Laughlin-Tommaso SK, Jensen JR, Coddington CC,
et al. Unilateral oophorectomy results in compensatory follicular recruitment
in the remaining ovary at time of ovarian stimulation for in vitro fertilization.
Fertil Steril 2014;101(3):7227.
[38] Zhai A, Axt J, Hamilton EC, Koehler E, Lovvorn HN. Assessing gonadal function
after childhood ovarian surgery. J Pediatr Surg 2012;47(6):12729.
[39] Fauvet R, Demblocque E, Morice P, Querleu D, Gondry J, Dara E. [Comparison
of epidemiological factors between serous and mucinous borderline ovarian
tumors: therapeutic implications]. Bull Cancer 2012;99(5):5516.
[40] Gotlieb WH, Flikker S, Davidson B, Korach Y, Kopolovic J, Ben-Baruch G.
Borderline tumors of the ovary: fertility treatment, conservative management,
and pregnancy outcome. Cancer 1998;82(1):1416.
[41] Morris RT, Gershenson DM, Silva EG, Follen M, Morris M, Wharton JT. Outcome
and reproductive function after conservative surgery for borderline ovarian
tumors. Obstet Gynecol 2000;95(4):5417.
[42] Uzan C, Muller E, Kane A, Gouy S, Bendifallah S, Fauvet R, et al. Fertility sparing
treatment of recurrent stage I serous borderline ovarian tumours. Hum Reprod
2013;28(12):32226.
[43] Palomba S, Zupi E, Russo T, Falbo A, Del Negro S, Manguso F, et al. Comparison
of two fertility-sparing approaches for bilateral borderline ovarian tumours: a
randomized controlled study. Hum Reprod 2007;22(2):57885.
[44] Koskas M, Uzan C, Gouy S, Pautier P, Lhomme C, Haie-Meder C, et al. Fertility
determinants after conservative surgery for mucinous borderline tumours of
the ovary (excluding peritoneal pseudomyxoma). Hum Reprod 2011;26(4):
80814.
[45] Rossing MA, Tang M-TC, Flagg EW, Weiss LK, Wicklund KG. A case-control
study of ovarian cancer in relation to infertility and the use of ovulationinducing drugs. Am J Epidemiol 2004;160(11):10708.
[46] Fortin A, Morice P, Thoury A, Camatte S, Dhainaut C, Madelenat P. Impact of
infertility drugs after treatment of borderline ovarian tumors: results of a
retrospective multicenter study. Fertil Steril 2007;87(3):5916.
[47] Basille C, Olivennes F, Le Calvez J, Beron-Gaillard N, Meduri G, Lhomme C, et al.
Impact of gonadotrophins and steroid hormones on tumour cells derived from
borderline ovarian tumours. Hum Reprod 2006;21(12):32415.
[48] Beiner ME, Gotlieb WH, Davidson B, Kopolovic J, Ben-Baruch G. Infertility
treatment after conservative management of borderline ovarian tumors.
Cancer 2001;92(2):3205.
[49] Van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AMG, Lambalk CB, Kortman
M, et al. Risk of borderline and invasive ovarian tumours after ovarian
stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod
2011;26(12):345665.
[50] Mantzavinos T, Kanakas N, Genatas C, Papadias K, Zourlas PA. Five years
follow-up in two patients with borderline tumours of the ovary hyperstimulated by gonadotrophin therapy for in-vitro fertilization. Hum Reprod 1994;
9(11):20323.
639